Table 1

Subject characteristics

SLE
(n=19)
NHC
(n=9)
P
SLE/NHC
SLE SNT+
(n=8)
SLE SNT−
(n=11)
P
SNT+/SNT−
Age42.3±10.139±11.90.45034.7±7.447.8±8.20.002
Sex: female17 (90%)100%0.3127 (88%)10 (91%)0.811
Ethnicity0.7310.207
Latino/Hispanic4 (21%)3 (33%)3 (38%)1 (9%)
Asian1 (5%)1 (11%)1 (13%)0
African-American13 (69%)5 (56%)4 (50%)9 (82%)
Caucasian1 (5%)001 (9%)
Education13.4±2.515.6±1.90.02814.9±2.712.3±1.70.035
No computer experience3 (16%)00.20703 (27%)0.228
Disease duration14.2±9.310.0±4.417.3±10.80.063
SLEDAI2.2±2.14.0±1.90.82±1.00.000
PGA0.38±0.43.61±0.48.22±0.310.042
SLICC DI1.0±1.1.9±1.41.0±1.00.819
Medications
Current prednisone (mg/day)2.4±3.62.8±3.62.1±3.70.658
Current HCQ16 (84%)6 (75%)10 (91%)0.348
Current DMARD10 (53%)4 (50%)6 (55%)0.845
Serology
Anti-dsDNA ab+16 (84%)8 (100%)8 (73%)0.228
Anti-Ro+15 (79%)6 (75%)9 (82%)0.719
Anti-ribosomal P+2 (11%)2 (25%)00.164
DNRAb+9 (47%)1 (11%)2 (25%)7 (64%)0.096
Low C34 (21%)3 (38%)1 (9%)0.134
Low C43 (16%)3 (38%)00.058
STAI31.6±9.125.1±5.20.06027.6±8.234.5±9.00.109
BDI7.5±5.51.8±2.40.0017.4±6.37.6±5.10.922
ANAM tests
Matching grids26.8±8.133.8±13.20.17227.8±10.926.1±5.80.674
Match to sample20.2±6.930.1±13.90.07121.7±6.019.1±7.50.432
CPT69.7±17.480.7±14.40.11473.4±15.367.0±190.445
Spatial navigation tests
Target success8 (42%)7 (78%)0.08
Total number of moves33.3±4.835.4±5.80.3132.8±3.733.7±5.60.67
Total area of map searched18.0±3.519.0±5.30.5516.1±2.919.3±3.30.04
Total number of turns23.9±5.923.8±4.90.9420.5±4.126.5±6.00.03
  • ANAM, Automated Neuropsychological Assessment Metric; BDI, Beck Depression Inventory; CPT, continuous processing test; DMARD, disease-modifying antirheumatic drug (two azathioprine, one methotrexate, seven mycophenolate mofetil); HCQ, hydroxychloroquine; NHC, healthy controls that had neuropsychological testing; PGA, Physician’s Global Assessment; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SLICC DI, Systemic Lupus International Collaborating Clinics Damage Index; STAI, State Trait Anxiety Inventory.